TL;DR
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein originally isolated from human gastric juice. With over 500 peer-reviewed preclinical publications since 1991, it is one of the most extensively studied research peptides in tissue biology, demonstrating apparent cytoprotective activity across gastric, musculoskeletal, vascular, and neurological research models.
Research use only. BPC-157 has not received FDA approval for any human therapeutic indication and is sold strictly for in-vitro laboratory research purposes.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein originally isolated from human gastric juice. With over 500 peer-reviewed preclinical publications since 1991, it is one of the most extensively studied research peptides in tissue biology, demonstrating apparent cytoprotective activity across gastric, musculoskeletal, vascular, and neurological research models.
Research-grade BPC-157 is supplied as a lyophilized powder with batch-specific Certificate of Analysis verification at ≥99% purity by HPLC.
Molecular Properties
| Property | Value |
|---|---|
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular weight | 1,419.53 g/mol |
| Amino acid count | 15 |
| Purity standard | ≥99% (HPLC verified) |
| Lyophilized storage | -20°C, 24–36 months |
| Reconstitution vehicle | Bacteriostatic water (primary), 0.6% acetic acid or saline (alternative) |
Proposed Mechanisms of Action
Published preclinical research has proposed several complementary mechanisms through which BPC-157 may exert observed effects in laboratory models. No single mechanism has been fully validated in human contexts.
Growth factor expression modulation
Rodent studies report BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts and interacts with FGFR and EGFR expression patterns in wound-cellular repair contexts.
Nitric oxide system interaction
Published work suggests BPC-157 counteracts vasoconstriction in experimental contexts via endothelial nitric oxide synthase pathway modulation.
VEGF pathway activation
Multiple studies report elevated VEGF expression in wound-cellular repair and ischemia models following BPC-157 administration.
Research Applications
Tissue repair models
Rodent incision, excision, tendon transection, and muscle crush models consistently examine BPC-157 effects on cellular repair kinetics, histological organization, and biomechanical properties.
Gastrointestinal research
The original research context: ethanol-, stress-, and NSAID-induced ulcer models plus DSS-induced colitis studies form a substantial literature subset.
Vascular and neurological models
Angiogenesis assays, ischemia-reperfusion studies, and TBI/stroke models represent more recent research directions.
Storage and Reconstitution
- Lyophilized at -20°C in original sealed vial; typical shelf life 24–36 months.
- Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is standard. Alternative vehicles include sterile saline or dilute acetic acid depending on experimental requirements.
- Reconstituted solution stored at 2–8°C, used within 7–28 days.
- Avoid repeated freeze-thaw of reconstituted peptide.
- Handling: Follow institutional biosafety protocols; use only in qualified research settings.
Regulatory Considerations
As of early 2026, BPC-157 has no investigational human therapeutic indication. The peptide continues to be available for strictly in-vitro research purposes when properly labeled, sold to qualified researchers, and handled under appropriate institutional biosafety protocols. Researchers should consult current FDA guidance and institutional policies before acquiring any research peptide.
Research Gaps
Despite the substantial published literature on BPC-157:
- Human pharmacokinetic and pharmacodynamic data remains limited.
- Proposed mechanisms require further validation in human-relevant systems.
- Long-term safety data across species is incomplete.
- Dose-response optimization for specific research applications continues to be an active research question.
- Independent cross-laboratory replication of specific findings is uneven across the literature.
These gaps represent ongoing research opportunities for careful, well-designed preclinical investigation using research-grade material with verified Certificate of Analysis.
Frequently Asked Questions
Is BPC-157 approved for human use?
No. BPC-157 has no investigational therapeutic indication. It is sold exclusively for in-vitro laboratory research in qualified research settings.
What purity standard should research-grade BPC-157 meet?
Quality research-grade material should be ≥99% purity as verified by HPLC with a batch-specific Certificate of Analysis. Aureum Peptides provides COAs with every shipment and maintains a searchable COA portal.
How is BPC-157 typically reconstituted for research?
Bacteriostatic water is the most common reconstitution vehicle. Alternative vehicles (sterile saline, dilute acetic acid) may be used depending on specific experimental protocols.
How long is reconstituted BPC-157 stable?
Once reconstituted, the peptide is generally stored at 2–8°C and used within 7–28 days depending on specific handling and vehicle. Avoid repeated freeze-thaw cycles.
Where can I verify the Certificate of Analysis for my batch?
Aureum Peptides includes a batch-specific COA with every shipment and maintains an online COA portal accessible using the batch number printed on your vial.
References
- Sikirić P et al. J Physiol Paris. 1991.
- Chang CH et al. Molecules. 2014.
- Sikirić P et al. J Physiol Pharmacol. 2003.
- Huang T et al. Drug Des Devel Ther. 2015.
- Seiwerth S et al. Curr Pharm Des. 2018.
(Reference list abbreviated. Full bibliography with DOIs available on request.)
Shop Research-Grade BPC-157
Order research-grade BPC-157 from Aureum Peptides: BPC-157 product page
All peptides ship with batch-specific Certificate of Analysis, ≥99% purity verification, and cold-chain logistics. Same-day dispatch on orders placed before 2:00 PM EST.
Disclaimer: This article summarizes published preclinical research for educational purposes to support qualified research activities. The information herein does not constitute research information, therapeutic claims, or recommendations for human use. BPC-157 is not approved by the FDA for any therapeutic indication. Always consult institutional policies and applicable regulations when conducting research with peptides.
Last reviewed: 2026-04-21
Author: Aureum Peptides Scientific Writing Team
Category: Tissue Biology Research
Tags: BPC-157, pentadecapeptide, tissue biology, wound healing research
